Great Bay Bio, a new biotechnology company dedicated to innovative drug CMC (Chemistry Manufacturing and Controls) and pre-clinical development of big data service platform, has been established in Hong Kong.
 
Dr. Michael Chan has been named chief executive officer. He will be tasked with formulating a sustainable development strategy for Great Bay Bio and be responsible for the overall operation and management of the enterprise. The headquarters will be based in Hong Kong and expand its business domestically and internationally. The company currently focuses on two major business lines: CMC platform technology services and product development, including two subsidiaries—Dongguan Taili Biotech and Guangdong Taili Biomedical Technology.
 
Great Bay Bio’s service platform of CMC/CDMO technology and pre-clinical research and big data development has a technical team of over 40 scientists and investigators. The team will offer an integrated service package with variability and customization.